1-Benzyl-5-pyrimidin-5-ylmethyl-2-thioxo-2,3-dihydro-1H-pyrimidin-4-one | 224777-57-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 1-Benzyl-5-pyrimidin-5-ylmethyl-2-thioxo-2,3-dihydro-1H-pyrimidin-4-one
• 英文别名: 1-Benzyl-5-(pyrimidin-5-ylmethyl)-2-sulfanylidenepyrimidin-4-one
• CAS: 224777-57-5
• 化学式: C₁₆H₁₄N₄OS
• 分子量: 310.379
• InChiKey: JHTGKAMOAVOJFB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  90.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-Benzyl-5-pyrimidin-5-ylmethyl-2-thioxo-2,3-dihydro-1H-pyrimidin-4-one 、 alkaline earth salt of/the/ methylsulfuric acid 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 1-Benzyl-2-benzylthio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one
  参考文献：
  名称：

  N-1 substituted pyrimidin-4-ones: novel, orally active inhibitors of lipoprotein-associated phospholipase A2

  摘要：

  From two related series of 2-(alkylthio)-pyrimidones, a novel series of 1-((amidolinked)-alkyl)-pyrimidones has been designed as nanomolar inhibitors of human lipoprotein-associated phopholipase A(2). These compounds show greatly enhanced activity in isolated plasma. Selected derivatives such as compounds 51 and 52 are orally active with a good duration of action. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00510-2
• 作为产物：
  描述：

  ethyl 3-(5-pyrimidinyl)acrylate 在 palladium on activated charcoal 草酰氯 、 氢气 、 sodium hydride 、 三乙胺 作用下， 以 乙二醇二甲醚 、 乙醇 、 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 生成 1-Benzyl-5-pyrimidin-5-ylmethyl-2-thioxo-2,3-dihydro-1H-pyrimidin-4-one
  参考文献：
  名称：

  N-1 substituted pyrimidin-4-ones: novel, orally active inhibitors of lipoprotein-associated phospholipase A2

  摘要：

  From two related series of 2-(alkylthio)-pyrimidones, a novel series of 1-((amidolinked)-alkyl)-pyrimidones has been designed as nanomolar inhibitors of human lipoprotein-associated phopholipase A(2). These compounds show greatly enhanced activity in isolated plasma. Selected derivatives such as compounds 51 and 52 are orally active with a good duration of action. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00510-2

文献信息

• [EN] PYRIMIDINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] COMPOSES DE PYRIMIDINONE ET COMPOSITIONS PHARMACEUTIQUES LES RENFERMANT
  申请人：SMITHKLINE BEECHAM PLC

  公开号：WO1999024420A1

  公开（公告）日：1999-05-20

  (EN) A group of novel pyrimidone compounds are inhibitors of the enzyme LDL PLA2 and therefore of use in treating atherosclerosis.(FR) L'invention concerne un groupe de nouveaux composés de pyrimidinone qui sont des inhibiteurs de l'enzyme LDL PLA2 et qui s'utilisent donc pour le traitement de l'athérosclérose.

  一组新型嘧啶酮化合物是LDL PLA2酶的抑制剂，因此可用于治疗动脉粥样硬化。
• Pyrimidinone compounds and pharmaceutical compositions containing them
  申请人：——

  公开号：US20020120139A1

  公开（公告）日：2002-08-29

  A group of novel pyrimidone compounds are inhibitors of the enzyme LDL PLA2 and therefore of use in treating atherosclerosis.

  一组新型嘧啶酮化合物是LDL PLA2酶的抑制剂，因此可用于治疗动脉粥样硬化。
• PYRIMIDINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
  申请人：SmithKline Beecham plc

  公开号：EP1028955B1

  公开（公告）日：2003-07-16
• US6417192B1
  申请人：——

  公开号：US6417192B1

  公开（公告）日：2002-07-09
• N-1 substituted pyrimidin-4-ones: novel, orally active inhibitors of lipoprotein-associated phospholipase A2
  作者：Helen F. Boyd、Stephen C.M. Fell、Sean T. Flynn、Deirdre M.B. Hickey、Robert J. Ife、Colin A. Leach、Colin H. Macphee、Kevin J. Milliner、Kitty E. Moores、Ivan L. Pinto、Rod A. Porter、D.Anthony Rawlings、Stephen A. Smith、Ian G. Stansfield、David G. Tew、Colin J. Theobald、Caroline M. Whittaker

  DOI：10.1016/s0960-894x(00)00510-2

  日期：2000.11

  From two related series of 2-(alkylthio)-pyrimidones, a novel series of 1-((amidolinked)-alkyl)-pyrimidones has been designed as nanomolar inhibitors of human lipoprotein-associated phopholipase A(2). These compounds show greatly enhanced activity in isolated plasma. Selected derivatives such as compounds 51 and 52 are orally active with a good duration of action. (C) 2000 Elsevier Science Ltd. All rights reserved.